Edition:
United Kingdom

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

6.95HKD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
HK$6.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,691,357
52-wk High
HK$9.86
52-wk Low
HK$3.95

Latest Key Developments (Source: Significant Developments)

Luye Pharma Group's Unit Luye Pharma Switzerland To Borrow EUR120 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT LUYE PHARMA SWITZERLAND TO BORROW EUR120 MILLION.LOAN UNDER FACILITY AGREEMENT WILL BE APPLIED TO REPAY UNIT'S SHAREHOLDER'S LOAN TO LOWER FINANCE COST OF GROUP.  Full Article

Luye Pharma Group Announces Approval For Clinical Trial Of Anti-Tumor Innovative Drug (LY01013) In China
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Luye Pharma Group Ltd <2186.HK>::ANNOUNCES APPROVAL FOR CLINICAL TRIAL FOR CLASS I NEW CHEMICAL DRUG, ANTI-TUMOR INNOVATIVE DRUG (LY01013) IN CHINA.  Full Article

Luye Pharma Says Unit Luye Hong Kong To Borrow Term Loan Of Up To $300 Mln
Thursday, 21 Jun 2018 

June 22 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT LUYE HONG KONG TO BORROW A TERM LOAN FACILITY OF UP TO US$300 MILLION.  Full Article

Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​
Monday, 26 Mar 2018 

March 26 (Reuters) - Luye Pharma Group Ltd <2186.HK>::BOARD DECLARED A FINAL DIVIDEND OF RMB0.045 PER SHARE.FY REVENUE UP 30.7% TO RMB3,814.8 MILLION.‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​.  Full Article

Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Luye Pharma Group Ltd <2186.HK>::COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT.‍PATENT INFRINGEMENT LAWSUIT ON GROUP'S RIVASTIGMINE 1 DAY PATCH​.‍NOVARTIS AG HAS REIMBURSED GROUP OF RELEVANT LEGAL EXPENSES ​.  Full Article

Luye Pharma Says ‍Unit Applies To Register For Proposed Issue Of Debt Securities
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Luye Pharma Group Ltd <2186.HK>::‍UNIT APPLIES TO NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS TO REGISTER FOR PROPOSED ISSUE OF DEBT SECURITIES.‍YANTAI LUYE ALSO INTENDS TO MAKE APPLICATION TO NAFMII FOR REGISTRATION OF PROPOSED ISSUE NOTES FOR AN AMOUNT OF UP TO RMB2 BILLION​.APPLIED FOR ISSUE OF DEBT SECURITIES OF UP TO RMB1.8 BILLION​.  Full Article

Luye Pharma says HY net profit RMB424.6 mln<2186.HK>
Monday, 29 Aug 2016 

Luye Pharma Group Ltd <2186.HK>: Announcement of interim results for the six months ended 30 June 2016 <2186.HK> . HY profit attributable to shareholders increased by RMB39.1 million or 10.2% to RMB424.6 million . Declared an interim dividend of RMB0.032 (equivalent to hk$0.037) per share for the six months ended 30 June 2016. . HY revenue increased by 6.1% to RMB1.49 billion . For the year of 2016, the group will continue to introduce measures to improve its profitability .  Full Article

Photo

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million (396.8 million pounds), as part of a strategy to focus on other therapy areas.